News
LQDA
76.49
+7.41%
5.28
GSK's Jemperli Delivers Promising Interim Data in Rectal Cancer
NASDAQ · 14h ago
Notable Monday Option Activity: CNMD, TRIP, LQDA
NASDAQ · 1d ago
Monday's ETF with Unusual Volume: PJP
NASDAQ · 1d ago
CG Oncology Stock Gains 12% in Three Months: What's Driving It?
NASDAQ · 1d ago
Weekly Report: what happened at LQDA last week (0706-0710)?
Weekly Report · 1d ago
Casey’s, Everspin, Liquidia, Upbound, Pampa: Insider Shockwave
TipRanks · 3d ago
Liquidia Insider Makes Major Move With High-Value Stock Sale
TipRanks · 6d ago
Liquidia director Stephen M. Bloch reports disposal of 75,000 common shares worth $6.02 million
PUBT · 6d ago
Major Insider Move Shakes Up Liquidia Technologies
TipRanks · 07/07 02:02
Liquidia director Stephen M. Bloch reports disposal of 25,000 common shares worth $1.99 million
PUBT · 07/06 21:45
5 Biotech Stocks That Delivered 100% To 300% Gains: Did Your Winning Trades Offset Portfolio Losses?
NASDAQ · 07/06 09:51
Weekly Report: what happened at LQDA last week (0629-0703)?
Weekly Report · 07/06 09:12
CYTK, PRME, DOCS, WBD, LQDA Trending With Analysts
TipRanks · 07/04 09:01
Liquidia Corporation (LQDA) Is Up 9.99% in One Week: What You Should Know
NASDAQ · 07/03 16:00
Liquidia Technologies (LQDA) Receives a Rating Update from a Top Analyst
TipRanks · 07/01 15:56
AstraZeneca's Enhertu Wins EU Nod for HER2-Positive Solid Tumors (Revised)
NASDAQ · 07/01 09:06
Applied Materials To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Monday
Benzinga · 06/29 13:05
This Liquidia Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday
Benzinga · 06/29 12:49
Liquidia Cut to Neutral From Buy by B of A Securities
Dow Jones · 06/29 12:09
Liquidia Price Target Raised to $79.00/Share From $64.00 by B of A Securities
Dow Jones · 06/29 12:09
More
Webull provides a variety of real-time LQDA stock news. You can receive the latest news about Liquidia Corporation through multiple platforms. This information may help you make smarter investment decisions.
About LQDA
Liquidia Corporation is a biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutic products for cardiopulmonary diseases. The Company operates within the biotechnology sector, focusing on treatments for conditions such as pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The Company operates through its wholly owned operating subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC. Its proprietary PRINT technology is a particle engineering platform, which enables precise production of uniform drug particles. Its lead product candidate is YUTREPIA for the treatment of PAH and PH-ILD. YUTREPIA is a PRINT‑engineered inhaled dry‑powder formulation of treprostinil designed to enhance deep lung delivery, improve therapeutic performance, and enable higher dose administration through a convenient inhaler.